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Atopic dermatitis is a chronic or recurrent inflammatory skin disease usually 
related to the atopic march and atopic morbidity. Although the onset of symptoms 
occurs predominantly at pediatric ages, the disease can start at any age and even the 
elderly.
A constellation of conditioning factors has been identified, most of them 
sustained by genetic and epigenetic aspects favoring a Th2 cell profile, intrinsi-
cally associated with many other factors of the skin itself, namely the localized 
immunoinflammatory responses, the skin barrier dysfunction, dysbiosis, neu-
roimmune dysregulation and obviously environmental determinants and many 
others conditions [1]. As a consequence, different phenotypes and endotypes 
result from multiple heterogeneous and complex pathogenic mechanisms that are 
clinically expressed with different levels of severity and in the specific location of 
the lesions [2].
At pediatric ages, the thickness of the skin is markedly reduced compared to 
adults, as well as the population and diversity of resident cells [3]. In case of skin 
inflammatory disease the homeostatic disruption on cells as well on the matrix 
structures determines intrinsic changes in the skin’s adaptive immunity facilitat-
ing an inducible skin-associated lymphoid tissue (iSALT) with critical conse-
quences [4].
The microbiome has a particular interest in all medical areas and aim of 
profuse scientific interest in the last decade. However, it was the results of the 
Sanford study that surprisingly came to prove the magnitude and diversity of 
cell-free DNA in our body [5]. In fact, the placental microbiome is decisive in the 
fetal period. So, gut and skin newborn microbial flora is markedly dependent on 
the maternal clinical condition and the type of delivery, eutocic or instrumented 
[6, 7]. However, the postnatal period, depending on intrinsic and exogenous 
factors, will allow the acquisition of new microorganisms. It therefore occurs a 
process of specialization in niches, and the subsequently interaction with the 
host comes to allow functional differentiations in this own flora having obvious 
consequences on mucosal structures [7].
The skin microbiota in the healthy individuals is highly variable between 
designated areas of moist, such as the surfaces of the antecubital and popliteal 
fossae, and areas of naturally drier skin or sebaceous skin areas, particularly 
regarding the proportions of the Phyla Actinobacteria, Firmicutes, Proteocbacteria e 
Bacteriodetes [8].
Dysbiosis in atopic dermatitis resulting from increased expression of 
Staphylococcus genera, particularly S aureus species, has been consensual for a 
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long time and the acute outbreaks had been frequently described corroborate this 
increase with a parallel decreases in Streptococcus or Propionibacterium species [9]. 
The overexposure in the skin of S aureus and, less frequently to Malassezia furfur, 
results on environment specific conditions that favor a local immunoinflammatory 
hyperactivation in opposition to the protective effect of Acinetobacter species [10].
Atopic dermatitis also has an apparent correlation between the intestinal 
axis and the cutaneous mucosa, with over-expression of Clostridium difficile 
and Faecalibacterium prausnitzii species, reduction of short-chain fatty acids 
metabolites, which may enable future and potential extra-cutaneous therapeutic 
implications [2, 9, 11, 12].
This recent data amplify the complexity of the pathophysiology and immuno-
logical mechanisms in atopic dermatitis already accepted, namely: the skin barrier 
dysfunction, the type 2 inflammatory immune response and other important cell 
axes such as the dependents of cell ways Th22, Th1, Th17 or JAK–STAT signaling 
pathway [13].
The enormous complexity of pathways and mechanisms involved in atopic 
dermatitis is based on a huge heterogeneity of polygenic determinisms, so the 
genome-wide association studies (GWAS) only allow confirming the heritability 
identification in a very limited number of patients. The best documented gene 
mutation is related to filaggrin, but is only present in around 30% of the European 
population [14]. Concerning skin barrier dysfunction other genes has been also 
described (loricrin, keratin-16 periplakin e SPINK5/LEKTI), but it requires more 
research to assess the magnitude and prevalence in a large patients samples studies 
[2]. Likewise for a typical type T2 inflammation the dysfunctions of IL-4 and IL-13 
loci are also far from being present in all patients [2].
Pruritus is one of the hallmarks of atopic dermatitis and can have a dramatic 
and severe impact on the quality of life of patients at all ages. From a clinical and 
pathophysiological point of view, the pruritus induced by histaminergic pathway 
is not a standard feature in opposition to other atopic diseases. In addition to the 
classic inflammatory type T2 cytokines (IL-4 and IL-13), the IL31 and, to a lesser 
extent, TSLP, are strictly related to pruritus signaling, particularly in severe forms. 
Despite the presence of IL-4Rα in afferent neural fibers, these neural structures also 
have IL-31Rα receptors, activated by the release of this cytokine by T2 cells, but also 
by mast cells, dendritic cells and activated keratinocytes [15].
Thus, pruritus is, rather than a clinical sign dependent on the inflammatory 
process, but itself an active intervening part on the pathogenic mechanism, 
allowing increased keratinocyte IL-31 release by damage and scratching, and 
also an increased activation of dermal dendritic cells via TSLP. Symptomatic 
control is, therefore, decisive, in terms of the immense discomfort experienced 
by the patient and also because allow a negative feedback to the underlying skin 
inflammation [13].
In the light of the above, inhibition of IL-4Rα receptors by dupilumab allows for 
a significant control of pruritus thresholds in a very expressive number of patients. 
However, in others, this control is not achieved. Trials with nemolizumab, an anti-
IL-31Rα monoclonal, look like it is highly effective in controlling itching, but with 
significant clinically adverse effects [15].
In an interesting experimental model with human mast cell lines, an alcoholic 
extract of Commiphora myrrha reduced not only the release of histamine, but also 
the production and release of IL-31 by kinase suppressor regulated by an extracel-
lular signal and activation of NF κB [16]. If these results are confirmed in vivo, this 
essential oil could have an enormous impact in the routine clinic associated with a 
reduced burden economic impact.
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The treatments currently recommended by different guidelines and consensus 
from different international scientific societies are strictly guiding in pharmaco-
logical and non-pharmacological care plans, namely: general measures, hydration 
to minimize barrier defects, topical treatments, systemic anti-inflammatory drugs 
for specific conditions and biological treatment for severe forms. Naturally, many 
of the new therapies are very expensive, which limits their access to many patients 
around the world [2, 13, 17].
However, several articles have pointed out other strategies that appear to be 
promising and highly elective in atopic dermatitis.
Emollients are essential to care, and it has been suggested an additional inclusion 
of ceramides or plant extracts with anti-inflammatory activity, despite the need for 
robust evidence [18–20].
Regarding anti-inflammatory therapy, the different classes of corticosteroids, 
calcineurin inhibitors and an inhibitor of the intracellular enzyme phosphodiester-
ase 4 represent the drugs currently available for topical treatment. Inhibitors of the 
JAK–STAT and tyrosine kinase pathways are currently in clinical trials. Delgocitinib 
(a pan-JAK inhibitor) has recently been approved in Japan for the treatment of 
adults with atopic dermatitis [2, 21].
Regarding systemic therapy it is recommended to severe presentations of atopic 
dermatitis, and in recent years it has been seen a profusion of new approaches with 
new biological drugs, some of them already available and many others in clinical 
trials [22, 23]. This topic is developed in a specific chapter in this book.
The spectrum of action of these new drugs, targeting glycoproteins (IgE), 
cytokines, chemokines (or their receptors), cell signaling pathways and cell surface 
receptors, should be submitted to a extensive drug-safety monitoring and rigourous 
pharmacovigilance programs, because most of them are generally ubiquitous in 
multiple cells, tissues and organs and could have potential uncontrolled conse-
quences, even in short-term treatments. In addition, this profusion of new drugs is 
not accompanied by biomarkers that allow a specific selection for different pheno-
types and endotypes, in a pathology as heterogeneous as atopic dermatitis.
The new data that comes from the knowledge of dysbiosis in atopic dermatitis 
must be consistent with new research lines. These findings will allow new thera-
peutic approaches in earlier stages and more primary pathophysiological conditions 
that support the immune-inflammatory process and support the chronicity and 
clinical severity.
The presence of cutaneous biofilms in severe clinical forms and with skin recur-
rent infections and impetiginization has extremely relevance on the clinical point 
of view [24]. Current treatment strategies do not establish nor allow the elimination 
of these structures on the skin surface. However, a growing number of in vivo and 
in vitro investigations have demonstrated that topical extracts of some medicinal 
plants had the ability of biofilms dysruption from bacteria (Staphilococcus spp e 
Streptococcus spp) or fungi (Malassesia furfur and Candida spp) [24, 25].
Like many other chronic conditions in which dysbiosis is subject to extensive 
research, also in allergic diseases and atopic dermatitis in particular, several studies 
sustain that in the treatment plan new approaches will be necessary, some of which 
with very promising in vitro and in vivo results [26]. There are countless potential 
manipulation and modulation possibilities of dysbiosis, but additional studies are 
still necessary to prove the efficiency and safety criteria [27].
Topical application of bacterial lysates or bacteriophage-derived enzymes seems 
to be one of the most feasible strategies. This strategy tends to, selective, replace 
strains considered commensal identified on the skin of healthy individuals or others 
comproved strains with competing effect for S aureus [27]. Another researches 
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address the topical application of non-replicating probiotics that may allow a nega-
tive modulation in the viability of dysbiotic bacterial flora [28].
Bacterial lysates administrated sublingually have been in clinical use since the 
1970s, for the prevention of infectious risk in respiratory pathology. Resulting from 
lysis of heat-inactivated bacterial strains, the composition can be selected and 
adjusted to a very diverse number of strains [29]. Without an obvious reason, its 
use in the clinic was markedly decrease in the late 1990s, but it has recently been a 
subject of interest and rediscovery given the potential of the mechanisms of action. 
In this context, the designation of “trained immunity-based vaccines” has been 
proposed since these vaccines allow effects on both innate and adaptive immunity 
[30, 31]. Among the most relevant mechanisms are the antimicrobial cytokine 
response, overexpression of TLRs; production of specific IgG and induction of 
regulatory T responses and regulation of dendritic cells [31]. In patients with 
strongly impetiginized forms, there is the possibility of personalized prescription 
with one extract containing strains adjusted to dysbiosis. This formulation adminis-
tred at sublingual region, adjacent to the MALT structure, is highly promising from 
an immune point of view, compared to the oral formulas, which is usually restricted 
to formulations and fixed compositions of lysates [32].
Other potential treatment strategies involve the autologous bacterial transplant, 
allogeneic bacterial transplant or even fecal microbial transplantation. On these 
grounds, further and roboust research is necessary [33–35].
Likewise, well-designed studies are needed to define the position and the role of 
probiotics, prebiotics or symbiotics in atopic dermatitis. This subject is developed 
in a chapter of this book, as well the specific criteria for phototherapy in select 
patients.
In view of the enormous clinical heterogeneity, of the physiopathological 
mechanisms, the treatment of atopic dermatitis is a real concern over the oppor-
tunities and therapeutic options already available and all other strategies under 
development and trials [2, 16–23, 36, 37].
So, nowadays the atopic dermatitis treatment is a real challenge in view of the 
enormous clinical heterogeneity, the physiopathological mechanisms, the immuno-
genic aspects and the tremendous variability regarding age, race and ethnicity [37].
In this context, the opportunities with the available therapeutics and all the 
other strategies under development will certainly allow us to increasingly personal-
ize the management plan and in a future that is believed to be close the identifica-
tion of robust biomarkers for phenotypes and endotyps, as also on monitoring 
approach.
The scientific review of some of these aspects in the chapters of this book will 
certainly be tools of great interest and importance in the knowledge of a pathology 
with colossal prevalence and a tremendous impact on the quality of life of these 
patients and their families.
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